Article
Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases - 1 Mar 2019
Pott-Junior H, Bricks G, Grandi G, Figueiredo Senise J, Castelo Filho A
Abstract excerpt
OBJECTIVE: To investigate the efficacy and safety of sofosbuvir (SOF) plus daclatasvir (DCV) or simeprevir (SMV) in a randomized, open-label, noninferiority trial of patients infected with hepatitis C virus genotype 1, who were previously unresponsive to pegylated interferon and ribavirin or were treatment naive. METHODS: Patients were randomly assigned to receive SOF (400 mg once daily) plus DCV (60 mg once...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.